SAN DIEGO, Nov. 29, 2016 /PRNewswire/ -- GenomeDx Biosciences today announced that ten presentations featuring Decipher® Prostate and Bladder data will be presented at the 17th Annual Meeting of the Society of Urologic Oncology (SUO), being held November 30 to December 2, 2016, at the Grand Hyatt San Antonio. Data presentations include four studies on Decipher Biopsy, five studies on Decipher Post-Op and one study focused on data highlights of GenomeDx's planned Decipher test for bladder cancer. "Collaboration with academic researchers is a key part of our strategy to use genomic information to improve management of patients with urologic cancers. The nine studies being presented from our Decipher Prostate Cancer Classifier tests showcase the depth of validation research we continue to conduct - with more than 4,000 samples already committed to studies for Decipher Biopsy alone," said Doug Dolginow, M.D., chief executive officer of GenomeDx. "In addition, we continue to see promising data come from our studies of the Decipher Bladder test, and will further evaluate this test's clinical potential." Decipher Biopsy Podium Presentation: Title: Evaluation of the Decipher Prostate Cancer Classifier to Predict Metastasis and Disease-Specific Mortality from Genomic Analysis of Diagnostic Prostate Needle Biopsy SpecimensPresentation Number: Oral abstract session, presentation #6Date: Friday, Dec. 2 ( 2:00 p.m. to 2:45 p.m. CST)Presenter: Voleak Choeurng, MSc., GenomeDx Biosciences Decipher Biopsy Poster Presentations: Title: Decipher Correlation Patterns on Biopsy: Initial Experience from 738 Prospective PatientsPresentation Number: 99Date: Wednesday, Nov. 30 ( 4:30 p.m. to 6:00 p.m. CST)Presenter: Ashley Ross, M.D., Ph.D., Johns Hopkins School of Medicine Title: The Heterogeneous Genomic Landscape of Low-Risk Prostate Cancer Presentation Number: 115Date: Wednesday, Nov. 30 ( 4:30 p.m. to 6:00 p.m. CST)Presenter: Matthew Cooperberg, M.D., MPH, University of California, San Francisco Title: Transcriptome Wide Analysis of MRI-Targeted Biopsy and Matching Surgical Specimens from High-Risk Prostate Cancer Patients Treated with Radical Prostatectomy Presentation Number: 126Date: Wednesday, Nov. 30 ( 4:30 p.m. to 6:00 p.m. CST)Presenter: Peter Black, M.D., University of British ColumbiaDecipher Post-Op Poster Presentations: Title: Decipher Test Impacts Adjuvant Treatment Decision-Making Among Patients with High-Risk Pathology at Radical Prostatectomy: Results from the Multicenter Prospective PRO-IMPACT Study Presentation Number: 75 Date: Wednesday, Nov. 30 ( 4:30 p.m. to 6:00 p.m. CST)Presenter: Daniel Lin, M.D., University of Washington Title: Decipher Test Impacts Treatment Decision-Making Among Patients with Biochemical Recurrence After Radical Prostatectomy: Results from the Multicenter Prospective PRO-IMPACT Study Presentation Number: 76Date: Wednesday, Nov. 30 ( 4:30 p.m. to 6:00 p.m. CST)Presenter: Daniel Lin, M.D., University of Washington Title: Assessing Decipher for Predicting Lymph Node Positive Disease Among Men Diagnosed with Intermediate Risk Disease Treated with Prostatectomy and EPLNDPresentation Number: 93Date: Wednesday, Nov. 30 ( 4:30 p.m. to 6:00 p.m. CST)Presenter: John Davis, M.D., The University of Texas MD Anderson Cancer Center Title: Individual Patient Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High Risk Men Post-Prostatectomy to Predict Development of Metastatic Disease Presentation Number: 94Date: Wednesday, Nov. 30 ( 4:30 p.m. to 6:00 p.m. CST)Presenter: Elai Davicioni, Ph.D., GenomeDx Biosciences Title: Comparative Analysis of the Decipher Genomic Classifier and CAPRA-S Nomogram Between African American and Caucasian PopulationsPresentation Number: 237Date: Thursday, Dec. 1 ( 4:55 p.m. to 6:25 p.m. CST)Presenter: Walter Rayford, M.D., Ph.D., University of TennesseeDecipher Bladder Poster Presentation: Title: Muscle Invasive Bladder Cancer: Molecular Subtypes are Related to Benefit of Neoadjuvant ChemotherapyPresentation Number: 143Date: Thursday, Dec. 1 ( 4:55 p.m. to 6:25 p.m. CST)Presenter: Peter Black, M.D., University of British ColumbiaAbout Decipher GRID® and Decipher® Prostate Cancer Classifier Tests GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.